NCT06564753View on ClinicalTrials.gov

Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

July 19, 2024

Primary Completion Date

February 27, 2025

Study Completion Date

April 18, 2025

Conditions
Weight LossObesityBody WeightBody Weight Changes
Interventions
DRUG

Drug: Placebo daily and orally

• Placebo comparator

DRUG

NA-931, dose 1, daily and orally

"Drug: NA-931 dose 1, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"

DRUG

NA-931, dose2, daily and orally

"Drug: NA-931 dose 2, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"

DRUG

NA-931 dose 3, daily and orally

"Drug: NA-931 dose 3, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"

DRUG

NA-931 dose 4, daily and orally

"Drug: NA-931 dose 4, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"

Trial Locations (5)

2050

Biomed Investigational Site, Camperdown

2065

Biomed Investigational Site, St Leonards

2291

Biomed Investigational Site, Merewether

3004

Biomed Investigational Site, Melbourne

3081

Biomed Investigational Site, Heidelberg Heights

All Listed Sponsors
lead

Biomed Industries, Inc.

INDUSTRY

NCT06564753 - Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition | Biotech Hunter | Biotech Hunter